natgillin/translations-raw huggingface dataset:
Hepatic events during post-marketing use have mainly been reported in patients that have been treated for Still's disease and in patients with predisposing factors, e.g. a history of transaminase elevations before start of Kineret treatment. 
Primeri jetrnih zapletov v času uporabe po začetku trženja so bili opisani pri bolnikih, ki so se zdravili za Stillovo bolezen, in pri bolnikih s predispozicijskimi dejavniki, npr. z anamnezo zvišanih vrednosti transaminaze pred začetkom zdravljenja z zdravilom Kineret.
In patients who become neutropenic (ANC < 1.5 x 109/l) the ANC should be monitored closely and Kineret treatment should be discontinued. 
Pri bolnikih, ki postanejo nevtropenični (ANC < 1,5 x 109/l), je treba skrbno spremljati ANC, zdravljenje z zdravilom Kineret pa je treba prekiniti.
Solution for injection in pre-filled syringe 1 GRADUATED pre-filled syringe 7 GRADUATED pre-filled syringes Multipack: 28 (4 x 7) GRADUATED pre-filled syringes 
raztopina za injiciranje v napolnjeni injekcijski brizgi 1 ODMERNA napolnjena injekcijska brizga 7 ODMERNIH napolnjenih injekcijskih brizg Skupno pakiranje: 28 (4 x 7) ODMERNIH napolnjenih injekcijskih brizg
In patients with severe renal impairment (CLcr <30 ml/min) or end stage renal disease, including dialysis, administration of the prescribed dose of Kineret every other day should be considered. 
Pri bolnikih s hudo ledvično okvaro (CLcr < 30 ml/min) ali končno ledvično odpovedjo, ki vključuje dializo, je treba razmisliti o dajanju predpisanega odmerka zdravila Kineret vsak drugi dan.
Kineret treatment significantly decreases the manifestations of CAPS, including a reduction in frequently occurring symptoms as fever, rash, joint pain, headache, fatigue, and eye redness. 
Zdravljenje z zdravilom Kineret znatno zmanjša pojav znakov CAPS, vključno z zmanjšanjem simptomov, ki se pogosto pojavljajo, kot so vročina, izpuščaji, bolečina v sklepih, glavobol, utrujenost in rdeče oči.
X-ray examinations have been undertaken in one clinical study with anakinra. 
V eni klinični študiji z anakinro so opravili rentgenske preiskave.
The recommended dose of Kineret is 100 mg administered once a day by subcutaneous injection. 
Priporočeni odmerek zdravila Kineret je 100 mg, enkrat na dan s subkutanim injiciranjem.
Symptoms might be persistent high fever, shivers, cough, headache, and redness and tenderness of the skin. 
Simptomi so lahko vztrajna zvišana telesna temperatura, mrzlica, kašelj, glavobol ter rdečina in občutljivost kože.
The graduated pre-filled syringe allows for doses between 20 and 100 mg. As the minimum dose is 20 mg the syringe is not suitable for paediatric patients with a body weight below 10 kg. 
Ker je najmanjši odmerek 20 mg, injekcijska brizga ni primerna za pediatrične bolnike s telesno maso pod 10 kg.
This is called a subcutaneous injection. 
Takšno injiciranje imenujemo podkožno (subkutano).
Still's disease: Data in elderly patients are limited. 
Stillova bolezen: Podatki pri starejših bolnikih so omejeni.
The median steady-state dose-normalized anakinra concentration in SJIA patients over 28 weeks was comparable to that observed in RA patients. 
Mediana koncentracija anakinre v stanju dinamičnega ravnovesja z normalizacijo odmerka pri bolnikih s SJIA v 28 tednu je bila primerljiva tisti pri bolnikih z RA.
This medicinal product contains less than 1 mmol sodium (23 mg) per 100 mg dose, that is to say essentially ‘sodium-free'. 
Vsebnost natrija To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na 100 mg, kar v bistvu pomeni „brez natrija“.
These elevations have not been associated with signs or symptoms of hepatocellular damage, except for one patient with SJIA that developed a serious hepatitis in connection with a cytomegalovirus infection. 
Ta zvišanja niso bila povezana z znaki ali simptomi hepatoceličnih okvar, razen pri enem bolniku s SJIA, pri katerem se je razvila resna oblika hepatitisa v povezavi s citomegalovirusno okužbo.
Blood cholesterol increase 
Zvišanje vrednosti holesterola v krvi
Concurrent Kineret and TNF-α antagonist treatment Concurrent administration of Kineret and etanercept has been associated with an increased risk of serious infections and neutropenia compared to etanercept alone in RA patients. 
Sočasno zdravljenje z zdravilom Kineret in antagonisti TNF-α Sočasno uporabo zdravila Kineret in etanercepta povezujejo z večjim tveganjem resnih okužb in nevtropenije v primerjavi z uporabo etanercepta samega pri bolnikih z RA.
Concurrent Kineret and TNF-α antagonist treatment In a clinical trial with RA patients receiving background methotrexate, patients treated with Kineret and etanercept were observed to have a higher rate of serious infections (7%) and neutropenia than patients treated with etanercept alone and higher than observed in previous trials where Kineret was used alone. 
V kliničnem preskušanju bolnikov z RA, ki so kot osnovno zdravilo dobivali metotreksat, so pri bolnikih, zdravljenih z zdravilom Kineret in etanerceptom, opazili večjo pogostost resnih okužb (7 %) in nevtropenije kot pri bolnikih, zdravljenih samo z etanerceptom, in tudi večjo kot v prejšnjih preskušanjih, v katerih so uporabljali samo zdravilo Kineret.
In clinical trials, whilst patients treated with Kineret had a higher incidence of lymphoma than the expected rate in the general population, this rate is consistent with rates reported in general for RA patients. 
V kliničnih preskušanjih pri bolnikih, zdravljenih z zdravilom Kineret, je bila incidenca limfomov sicer večja, kot je pričakovana v splošni populaciji, se je pa delež skladal z deležem, ki ga na splošno navajajo pri bolnikih z RA.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON OF 7 PRE-FILLED SYRINGES AS AN INTERMEDIATE PACK (WITHOUT BLUE BOX) 
ŠKATLA S 7 NAPOLNJENIMI INJEKCIJSKIMI BRIZGAMI KOT VMESNO PAKIRANJE (BREZ PODATKOV ZA MODRO OKENCE)
No dose adjustment is required for patients with moderate hepatic impairment (Child-Pugh Class B). 
Za bolnike z zmerno jetrno okvaro (razred Child-Pugh B) ni potrebna prilagoditev odmerka.
At a dose of 100 mg/day, 71% of RA patients developed an ISR compared to 28% of the placebo treated patients. 
Pri odmerku 100 mg/dan so se ISR razvile pri 71 % bolnikov z
Patients with trisomy 21 seem to be overrepresented. 
Prevladovali so bolniki s trisomijo 21.
The absorption process is the rate-limiting factor for the disappearance of anakinra from the plasma after subcutaneous injection. 
Dejavnik, ki omejuje hitrost izginjanja anakinre iz plazme po subkutani injekciji, je proces absorpcije.
The 50 patients who achieved a clinical response after a 12-week open-label run-in were randomized to Kineret (25 patients) or placebo (25 patients), administered daily for an additional 16 weeks. 
(25 bolnikov) ali placebo (25 bolnikov), ki so ga dnevno dobivali še nadaljnjih 16 tednov.
In clinical studies in RA patients, thrombocytopenia has been reported in 1.9% of treated patients compared to 0.3% in the placebo group. 
V kliničnih študijah bolnikov z RA so poročali o trombocitopeniji pri 1,9 % zdravljenih bolnikov v primerjavi z 0,3 % v skupini, ki je prejemala placebo.
In 15 SJIA patients followed for up to 1.5 years, one event of transient neutropenia was reported. 
Pri 15 bolnikih s SJIA, ki so jih spremljali do 1,5 leta, so poročali o enem primeru prehodne nevtropenije.
It may contain some translucent-to-white particles of protein. 
Vsebuje lahko nekaj prosojnih do belih beljakovinskih delcev.
If you develop signs of lung disease you should contact your health care provider as soon as possible. 
Če se pri vas pojavijo simptomi pljučne bolezni, se morate čim prej posvetovati z zdravnikom.
The most common reason for withdrawal from study in Kineret-treated RA patients was injection site reaction. 
Najpogostejši razlog za izstop bolnikov z RA, zdravljenih z zdravilom Kineret, iz študije je bila reakcija na mestu injiciranja.
In 43 CAPS patients followed for up to 5 years, no allergic event was serious and no event required discontinuation of Kineret treatment. 
Pri 43 bolnikih s CAPS, ki so jih spremljali do 5 let, ni bilo resnih alergijskih dogodkov in pri nobenem dogodku ni bilo treba prekiniti zdravljenja z zdravilom Kineret.
Uncommon (≥ 1/1,000 to < 1/100) Allergic reactions including anaphylactic reactions, angioedema, urticaria and pruritus 
nevtropenija trombocitopenija bolezni imunskega sistema občasni (≥ 1/1.000 do < 1/100) alergijske reakcije, vključno z anafilaktičnimi reakcijami in angioedemom, urtikarija in srbenje bolezni živčevja zelo pogosti (≥ 1/10)
Use of Kineret is not recommended during pregnancy and in women of childbearing potential not using contraception. 
Uporaba zdravila Kineret v nosečnosti in pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije, ni priporočljiva.
During post-marketing use of Kineret, thrombocytopenia has been reported, including occasional case reports indicating severe thrombocytopenia (i.e. platelet counts <10 x109/l). 
V času uporabe po začetku trženja zdravila Kineret so poročali o trombocitopeniji, vključno s posameznimi primeri, ki so kazali na hudo trombocitopenijo (tj. število trombocitov < 10 x 109/l) Alergijske reakcije
The recommended dose for patients weighing 50 kg or more is 100 mg/ day by subcutaneous injection. 
Priporočeni odmerek za bolnike s telesno maso 50 kg ali več je 100 mg/dan s subkutano injekcijo.
Patients weighing less than 50 kg should be dosed by body weight with a starting dose of 1-2 mg/kg/day. 
Bolnikom s telesno maso manj kot 50 kg je treba odmerek prilagoditi glede na telesno maso, začetni odmerek pa je 1-2 mg/kg/dan.
These data support that no dose adjustment is needed for patients with mild renal impairment (CLcr 50 to 80 ml/minute). 
Ti podatki potrjujejo, da pri bolnikih z blago ledvično okvaro (CLcr 50 do 80 ml/minuto) ni potrebno prilagajanje odmerka.
• The patient and caregiver guide 
• vodnik za bolnika in skrbnika,
This is a type of cytokine (an immunosuppressive agent) that is used to treat: - Rheumatoid Arthritis (RA) - Cryopyrin-Associated Periodic Syndromes (CAPS) which includes the following autoinflammatory diseases: - Neonatal-Onset Multisystem Inflammatory Disease (NOMID), also called Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA), - Muckle-Wells Syndrome (MWS), - Familial Cold Autoinflammatory Syndrome (FCAS) - Still´s disease including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD) 
- s kriopirinom povezanih periodičnih sindromov (CAPS - Cryopyrin-Associated Periodic Syndromes), ki vključujejo naslednje avtoinflamatorne bolezni: - multisistemsko vnetno bolezen z začetkom pri novorojenčku (NOMID- Neonatal-Onset Multisystem Inflammatory Disease), imenovano tudi kronični vnetni nevrološki, kožni in sklepni sindrom (CINCA - Chronic Infantile Neurological, Cutaneous, Articular Syndrome) - Muckle-Wellsov sindrom (MWS) - družinski avtoinflamatorni sindrom zaradi mraza (FCAS- Familial Cold Autoinflammatory Syndrome)
Cryopyrin-Associated Periodic Syndromes (CAPS) Kineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of CAPS, including: - Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, 
S kriopirinom povezani periodični sindromi (CAPS - Cryopyrin-Associated Periodic Syndromes) Zdravilo Kineret je indicirano pri odraslih, mladostnikih, otrocih in dojenčkih, starih 8 mesecev in več, s telesno maso 10 kg ali več, za zdravljenje CAPS, ki vključujejo: - multisistemsko vnetno bolezen z začetkom pri novorojenčku (NOMID - Neonatal-Onset
Therefore, screening for viral hepatitis should be performed in accordance with published guidelines also before starting therapy with Kineret. 
Drugi načini zdravljenja revmatičnih obolenj so bili povezani z reaktivacijo hepatitisa B. Zato je treba opraviti presejalne teste za virusni hepatitis v skladu z objavljenimi smernicami tudi pred začetkom zdravljenja z zdravilom Kineret.
In 15 SJIA patients followed for up to 1.5 years, no allergic event was serious and no event required discontinuation of Kineret. 
Pri 15 bolnikih s SJIA, ki so jih spremljali do 1,5 leta, ni bilo resnih alergijskih dogodkov in pri nobenem dogodku ni bilo treba prekiniti zdravljenja z zdravilom Kineret.
- Increased total blood cholesterol levels. 
- glavoboli; - zvišana raven skupnega holesterola v krvi.
Mild thrombocytopenia has also been observed in CAPS patients. 
Blago trombocitopenijo so opazili tudi pri bolnikih s CAPS.
In a clinical study including 43 adult and paediatric patients (36 patients aged 8 months to < 18 years) with severe CAPS (NOMID/CINCA and MWS), a clinical response to anakinra was seen within 10 days after initiation of treatment in all patients and was sustained for up to 5 years with the continued administration of Kineret. 
(36 bolnikov, starih od 8 mesecev do < 18 let) s hudimi CAPS (NOMID/CINCA in MWS), so pri vseh bolnikih v 10 dneh po uvedbi zdravljenja opazili klinični odziv na anakinro, ki se je obdržal do 5 let pri nadaljnjem dajanju zdravila Kineret.
- The other ingredients are anhydrous citric acid, sodium chloride, disodium edetate dihydrate, polysorbate 80 and sodium hydroxide and water for injections. 
- Druge sestavine so: brezvodna citronska kislina, natrijev klorid, dinatrijev edetat dihidrat, polisorbat 80 in natrijev hidroksid in voda za injekcije.
0.67 ml of solution for injection in a graduated pre-filled syringe (Type I glass) with a plunger stopper (bromobutyl rubber) and 29 gauge needle. 
0,67 ml raztopine za injiciranje v odmerni napolnjeni injekcijski brizgi (iz stekla tipa I) z batnim zamaškom (iz bromobutilne gume) in iglo velikosti 29 G. Napolnjena injekcijska brizga ima na notranji pokrovček igle pritrjen zunanji togi plastičen ščit.
The incidence of serious infections in RA studies conducted at the recommended dose (100 mg/day) was 1.8% in Kineret treated patients and 0.7% in placebo-treated patients. 
Incidenca resnih okužb v študijah RA, opravljenih s priporočenim odmerkom (100 mg/dan) je bila 1,8 % pri bolnikih, zdravljenih z zdravilom Kineret, in 0,7 % pri bolnikih, ki so dobivali placebo.
To give yourself or your child a subcutaneous injection you will need: 
Da boste dali podkožno injekcijo sebi ali svojemu otroku, potrebujete: • napolnjeno injekcijsko brizgo zdravila Kineret
In 15 SJIA patients followed for up to 1.5 years, the most common and consistently reported treatment-related adverse reactions associated with Kineret treatment were ISRs. 
Pri 15 bolnikih s SJIA, ki so jih spremljali do 1,5 leta, so najpogosteje in najbolj dosledno poročali o neželenih učinkih ISR v povezavi z zdravljenjem z zdravilom Kineret.
Breast-feeding should be discontinued during treatment with Kineret. 
Med zdravljenjem z zdravilom Kineret je treba prenehati z dojenjem.
Clear, colourless-to-white solution for injection that may contain some product-related translucentto-white amorphous particles. 
Bistra, brezbarvna do bela raztopina za injiciranje, ki lahko vsebuje nekaj prosojnih do belih amorfnih delcev.
There may be some translucent-to-white particles of protein in the solution. 
V raztopini je lahko nekaj prosojnih do belih beljakovinskih delcev.
• That it is not recommended to start treatment with Kineret in patients with an ongoing infection 
• da pri bolnikih s trenutno okužbo ni priporočljivo začeti zdravljenja z zdravilom Kineret,
Patients should be screened for latent tuberculosis prior to initiating Kineret. 
Pred začetkom zdravljenja z zdravilom Kineret bi bilo treba pri bolnikih opraviti preventivni pregled glede latentne tuberkuloze.
Excipients: anhydrous citric acid, sodium chloride, disodium edetate dihydrate, polysorbate 80, sodium hydroxide, water for injections. 
Pomožne snovi: brezvodna citronska kislina, natrijev klorid, dinatrijev edetat dihidrat, polisorbat 80, natrijev hidroksid, voda za injekcije.
In 43 CAPS patients followed for up to 5 years the frequency of serious infections was 0.1/year, the most common being pneumonia and gastroenteritis. 
Pri 43 bolnikih s CAPS, ki so jih spremljali do 5 let, je bila pogostnost resnih okužb 0,1/leto,
The safety and efficacy of Kineret versus DMARD have been reported in a published 24-week multicenter, randomized, open-label study of 22 patients with glucocorticoid-dependent refractory AOSD. 
24-tedenski multicentrični, randomizirani, odprti študiji z 22 bolniki z refraktarno AOSD, odvisno od glukokortikoidov.
Patients are usually well-controlled by maintaining the recommended starting dose (1-2 mg/kg/day). 
Vzdrževalni odmerek pri blagih CAPS (FCAS, blagi MWS) Pri bolnikih je z vzdrževanjem priporočenega začetnega odmerka (1-2 mg/kg/dan) bolezen navadno dobro urejena.
There is limited experience in treating elderly CAPS and Still's disease patients. 
Izkušnje pri zdravljenju starejših bolnikov s CAPS in Stillovo boleznijo so omejene.
For single use only. 
Namenjen je samo za enkratno uporabo.
Spontaneous mutations in the CIAS1/NLRP3 gene have been identified in a majority of patients with CAPS. 
Pri večini bolnikov s CAPS so bile ugotovljene spontane mutacije gena CIAS1/NLRP3.
Uncommon (≥ 1/1,000 to < 1/100) Hepatic enzyme increased Not known (cannot be estimated from the available data) 
(< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Kineret has been associated with an increased incidence of serious infections (1.8%) vs. placebo (0.7%) in RA patients. 
Zdravilo Kineret povezujejo z zvečano incidenco resnih okužb (1,8 %) v primerjavi s placebom (0,7 %) pri bolnikih z RA.
- if you get a rash all over your body, shortness of breath, wheezing, fast pulse or sweating after your Kineret injection. 
Nemudoma se obrnite na svojega zdravnika če se po injekciji zdravila Kineret pojavi izpuščaj po vsem telesu, kratka sapa, sopenje, hiter srčni utrip ali znojenje.
The patient and caregiver information pack should contain: 
Izobraževalni paket za bolnika in skrbnika mora vključevati:
Cooling of the injection site, warming the injection liquid to room temperature, use of cold packs (before and after the injection), and use of topical glucocorticoids and antihistamines after the injection can alleviate the signs and symptoms of injection site reactions. 
(pred in po injiciranju) in uporaba topikalnih glukokortikoidov in antihistaminikov po injiciranju lahko ublažijo znake in simptome reakcije na mestu injiciranja.
Consequently plasma clearance of Kineret decreases with decreasing renal function. 
Posledično se z zmanjšanim delovanjem ledvic zmanjša tudi plazemski očistek zdravila Kineret.
Do not inject more Kineret. 
Napolnjene injekcijske brizge ne stresajte.
Contents of the pack and other information 
Shranjevanje zdravila Kineret Vsebina pakiranja in dodatne informacije
During post-marketing use hepatic events, not affecting liver function, have been reported. 
V času uporabe po začetku trženja so poročali o jetrnih zapletih, ki niso vplivali na delovanje jeter.
A total of 752 RA patients ≥ 65 years of age, including 163 patients ≥ 75 years of age, were studied in clinical trials. 
V kliničnih preskušanjih so proučili skupaj 752 bolnikov z RA, starih 65 let ali več, med njimi je bilo 163 bolnikov, starih 75 let ali več.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING PRE-FILLED SYRINGE CARTON (CONTAINS BLUE BOX) 
ŠKATLA Z NAPOLNJENIMI INJEKCIJSKIMI BRIZGAMI (VSEBUJE PODATKE MODREGA OKENCA)
• Instructions on use of the syringe 
• navodila za uporabo injekcijske brizge,
Clinical efficacy and safety in Still's disease 
Klinična učinkovitost in varnost pri Stillovi bolezni
No dose-limiting toxicities were observed during clinical studies. 
Med kliničnimi študijami niso opazili toksičnosti, ki bi omejevale odmerek.
The adverse reactions table below therefore applies to Kineret treatment of RA, CAPS and Still's disease. 
Preglednica neželenih učinkov spodaj zato velja za zdravljenje RA, CAPS in Stillove bolezni z zdravilom Kineret.
Disinfect the skin by using the alcohol wipe and pinch the skin between your thumb and forefinger, without squeezing it. 
Nato kožo primite med palec in kazalec, ne da bi jo stiskali.
No data are available on the effects of vaccination with other inactivated antigens in patients receiving Kineret. 
Za bolnike, ki so dobivali zdravilo Kineret, ni podatkov o učinkih cepljenja z drugimi inaktiviranimi antigeni.
Pharmacokinetic data are lacking in older CAPS patients. 
Za starejše bolnikih s CAPS ni podatkov o farmakokinetiki.
A causal relationship with Kineret has not been established. 
Vzročna povezava z zdravilom Kineret ni bila ugotovljena.
Discard any unused medicinal product. 
Zavrzite celotno količino neuporabljenega zdravila.
Method of administration Kineret is administered by subcutaneous injection. 
Zdravilo Kineret se daje s subkutanim injiciranjem.
A corresponding decrease in creatinine clearance was seen in the hepatic failure population. 
Pri populaciji z odpovedjo jeter so opazili ustrezno zmanjšanje očistka kreatinina.
Kineret is a clear, colourless-to-white solution for injection and is supplied ready for use in a pre-filled syringe. 
Zdravilo Kineret je bistra, brezbarvna do bela raztopina za injiciranje, opremljena v napolnjenih injekcijskih brizgah, pripravljenih za uporabo.
Kineret was commonly associated with neutropenia (ANC < 1.5 x 109/l) in placebo-controlled studies in RA and cases of neutropenia have been observed in patients with CAPS and Still's disease. 
Pri s placebom nadzorovanih študijah RA je bilo zdravilo Kineret pogosto povezano z nevtropenijo (ANC < 1,5 x 109/l) in pri bolnikih s CAPS in Stillovo boleznijo so bili zabeleženi primeri nevtropenije.
Juvenile rats treated at doses up to 100 times the human dose from day 7 postparturition up to adolescence did not show any signs of adverse effects of the treatment. 
Juvenilne podgane, ki so bile od 7. dneva po porodu do adolescence zdravljene v odmerkih, do
Most patients continued on study medicinal product after the infection resolved. 
Potem ko se je okužba pozdravila, je večina bolnikov nadaljevala s proučevanim zdravilom.
The patient and caregiver guide shall contain the following key elements: 
Vodnik za bolnika in skrbnika mora vključevati naslednje ključne elemente:
Physicians should exercise caution when administering Kineret to patients with a history of recurring infections or with underlying conditions which may predispose them to infections. 
Pri predpisovanju zdravila Kineret bolnikom z anamnezo ponavljajočih se okužb ali z osnovnimi boleznimi, zaradi katerih bi lahko postali dovzetnejši za okužbe, morajo biti zdravniki previdni.
IL-1 is found in the plasma and synovial fluid of patients with rheumatoid arthritis, and a correlation has been reported between IL-1 concentrations in the plasma and the activity of the disease. 
Poročali so o korelaciji med koncentracijami IL-1 v plazmi in aktivnostjo bolezni.
Physicians should be attentive to symptoms of infection or worsening of Still's disease, as these are known triggers for MAS. 
Zdravniki morajo biti pozorni na simptome okužbe ali poslabšanja
Kineret contains sodium 
Zdravilo Kineret vsebuje natrij
• Do not put the cover back on used needles. 
Odlaganje uporabljenih brizg in potrebščin • Ne nameščajte pokrovčka nazaj na uporabljene igle.
In addition, postmarketing adverse event reports and published studies constitute supporting data. 
Podporne podatke predstavljajo tudi poročila o neželenih učinkih med uporabo po začetku trženja in objavljene študije.
In addition cases of non-infectious hepatitis, including occasional events of acute liver failure, have been reported in patients with Still's disease during Kineret treatment. 
Poleg tega so pri bolnikih s Stillovo boleznijo med zdravljenjem z zdravilom Kineret poročali o primerih neinfekcijskega hepatitisa, vključno z občasnimi dogodki akutne odpovedi jeter.
In a placebo-controlled clinical trial (n = 126), no difference was detected in anti-tetanus antibody response between the Kineret and placebo treatment groups when a tetanus/diphtheria toxoid vaccine was administered concurrently with Kineret. 
V kliničnem preskušanju (n = 126), kontroliranem s placebom, so sočasno z zdravilom Kineret uporabili toksoid tetanusa/davice.